July 06, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Phase 2 study begins for noninfectious uveitis candidate filgotinib
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
A phase 2 study of filgotinib, a noninfectious uveitis candidate from Galapagos NV, has begun, according to a company press release.
The trial, led by collaboration partner Gilead Sciences, will evaluate the safety and efficacy of filgotinib vs. placebo administered for 52 weeks in 110 adult patients with active noninfectious uveitis.
The primary goal at 24 weeks will be the proportion of patients who fail treatment, represented by an active uveitis flare.
The drug is also in clinical trials to evaluate its efficacy in cutaneous lupus erythematosus, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.